RT Journal Article
SR Electronic
T1 SARS-Cov-2 RNA Found on Particulate Matter of Bergamo in Northern Italy: First Preliminary Evidence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20065995
DO 10.1101/2020.04.15.20065995
A1 Leonardo Setti
A1 Fabrizio Passarini
A1 Gianluigi De Gennaro
A1 Pierluigi Barbieri
A1 Maria Grazia Perrone
A1 Massimo Borelli
A1 Jolanda Palmisani
A1 Alessia Di Gilio
A1 Valentina Torboli
A1 Alberto Pallavicini
A1 Maurizio Ruscio
A1 Prisco Piscitelli
A1 Alessandro Miani
YR 2020
UL http://medrxiv.org/content/early/2020/04/24/2020.04.15.20065995.abstract
AB In previous communications, we have hypothesized the possibility that SARS-CoV-2 virus could be present on particulate matter (PM) during the spreading of the infection, consistently with evidence already available for other viruses. Here, we present the first results of the analyses that we have performed on 34 PM10 samples of outdoor/airborne PM10 from an industrial site of Bergamo Province, collected with two different air samplers over a continuous 3-weeks period, from February 21st to March 13th. We can confirm to have reasonably demonstrated the presence of SARS-CoV-2 viral RNA by detecting highly specific RtDR gene on 8 filters in two parallel PCR analyses. This is the first preliminary evidence that SARS-CoV-2 RNA can be present on outdoor particulate matter, thus suggesting that, in conditions of atmospheric stability and high concentrations of PM, SARS-CoV-2 could create clusters with outdoor PM and, by reducing their diffusion coefficient, enhance the persistence of the virus in the atmosphere. Further confirmations of this preliminary evidence are ongoing, and should include real-time assessment about the vitality of the SARS-CoV-2 as well as its virulence when adsorbed on particulate matter. At the present, no assumptions can be made concerning the correlation between the presence of the virus on PM and COVID-19 outbreak progression. Other issues to be specifically addressed are the average concentrations of PM eventually required for a potential boost effect of the contagion (in case it is confirmed that PM might act as a carrier for the viral droplet nuclei), or even the theoretic possibility of immunization consequent to minimal dose exposures at lower thresholds of PM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon reasonable requests